Medtentia International develops medical device products for the treatment of mitral insufficiency – the most common type of mitral valve regurgitation requiring surgical treatment. Mitral insufficiency occurs in approximately 10 percent of the population above the age of 75 and can lead to heart failure. However, around half of patients are medically unsuitable for the major surgical procedure that currently represents the standard method for restoring the valve’s function. There is thus a major medical need for less invasive types of treatment.

www.medtentia.com